title: Targeting cytomegalovirus during ulcerative colitis flare-ups.
abstract: Human cytomegalovirus (CMV) is a common cause of opportunistic infection leading to severe and fatal disease in immune-compromised individuals. In inflammatory bowel disease patients, particularly those with ulcerative colitis (UC), CMV is often reactivated because these patients are frequently treated with immunosuppressive agents. Many reports have described the relationship between CMV reactivation and UC exacerbation, however, a therapeutic strategy for CMV infection in UC patients has not been established. Area covered: This review highlights therapeutic strategies for UC patients with CMV infection. Recent findings have suggested a benefit from antiviral therapy in patients with histologically proven CMV colitis and/or a high colonic CMV load as determined by quantitative PCR. Expert commentary: To decide who requires antiviral therapies and when we start antiviral therapies, prospective studies of large numbers of UC patients with CMV infection are needed. However, we should know that the bottom-line therapy for UC patients with CMV infection is to optimally control mucosal inflammation.
authors.affiliation: a Department of Gastroenterology, and Hepatology , Sapporo Medical University School of Medicine , Sapporo , Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakase
authors.affiliation: a Department of Gastroenterology, and Hepatology , Sapporo Medical University School of Medicine , Sapporo , Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Onodera
keywords: Cytomegalovirus; TNF-α; antiviral therapy; mucosal PCR; ulcerative colitis